-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chuangsheng Group, a clinical stage international biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical research and development, clinical and process development and production, today announced that it will pass the abstract online at the 57th American Society of Clinical Oncology (ASCO) The method of publication announced the update of the safety and efficacy data of the phase I clinical study of its pH-dependent PD-L1 antibody MSB2311 in patients with advanced solid tumors and hematological malignancies in China
.
This annual meeting will be held in the form of a virtual meeting from June 4 to 8, 2021, Eastern Time
Published online
title:
Updated safety and efficacy of MSB2311 (an Anti-Programmed Death-Ligand 1 Antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase I study.
Update on the safety and efficacy data of the Phase I clinical study of pH-dependent PD-L1 antibody MSB2311 in patients with advanced solid tumors and hematological malignancies in China
Abstract Number: e14547
First author:
Shen Lin, Doctor of Medicine (Peking University Cancer Hospital)
About MSB2311:
MSB2311 is a humanized antibody that binds to PD-L1 in a pH-dependent manner
.
PD-L1 is involved in suppressing the immune system response against cancer